Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Gossamer Bio is expecting to submit seralutinib's NDA for pulmonary arterial hypertension (PAH) in early September, followed by a potential filing acceptance after a 75-day review and a Prescription Drug User Fee Act (PDUFA) action date in 2027. They have recently completed a convertible note exchange offer and consent solicitation which will provide them with the necessary funding to support their operations through potential approval. Despite the potential dilution from the exchange, Gossamer Bio's focus on a totality-of-evidence NDA filing strategy, along with strong support from key opinion leaders and a broad commercial opportunity, supports a positive outlook on the stock.

Bears say

Gossamer Bio is facing significant challenges as a clinical-stage biopharmaceutical company due to its pipeline being centered primarily on one product, seralutinib, and its potential use in treating PAH. While the CT FRI data and PROSERA trial results have increased enthusiasm surrounding this product, there are concerns about the drug's safety, particularly related to liver enzyme elevations, and its potential for cough as a side effect. These issues may hamper the drug's approval and commercial success, leading to a negative outlook for the company's stock.

GOSS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 7 analysts, GOSS has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.